Skip to content

Glaukos GKOS Restricted Cash

Restricted Cash at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Boston Scientific logo
Boston ScientificBSX
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsNoncurrent.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's restricted cash?
Glaukos (GKOS) reported restricted cash of $3.83M in Q1 2026.
How has Glaukos's restricted cash changed year-over-year?
Glaukos's restricted cash decreased by 19.0% year-over-year, from $4.73M to $3.83M.
What is the long-term trend for Glaukos's restricted cash?
Over 5 years (2020 to 2025), Glaukos's restricted cash has grown at a -16.7% compound annual growth rate (CAGR), from $9.57M to $3.83M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.